Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1.

Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1.

Detalles Bibliográficos
Autores principales:	Slavin, S, Or, R, Weiss, L, Steiner-Zalz, D, Cividalli, G, Brautbar, C, Weshler, Z, Galun, E, Samuels, S, Galili, D
Formato:	Journal article
Lenguaje:	English
Publicado:	1985

Ejemplares similares

Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1).
por: Waldmann, H, et al.
Publicado: (1984)

ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES
por: Naparstek, E, et al.
Publicado: (1993)

Allogeneic bone marrow transplantation without graft-v-host disease: true tolerance of graft against the host through depletion of donor T lymphocytes pregrafting in malignant and nonmalignant disorders.
por: Slavin, S, et al.
Publicado: (1987)

PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA BY T-CELL DEPLETION INVITRO PRIOR TO TRANSPLANTATION
por: Slavin, S, et al.
Publicado: (1985)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
por: Naparstek, E, et al.
Publicado: (1999)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
por: Hale, G, et al.
Publicado: (1988)

New approaches for the prevention of rejection and graft-vs.-host disease in clinical bone marrow transplantation.
por: Slavin, S, et al.
Publicado: (1986)

T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse.
por: Naparstek, E, et al.
Publicado: (1995)

Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases.
por: Hale, G, et al.
Publicado: (1994)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
por: Fibbe, W, et al.
Publicado: (1993)

Induction of anti-leukemic responses by stimulation of leukemic CD3+ cells with allogeneic stimulator cells
por: Alejandro Pando, et al.
Publicado: (2018-10-01)

T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
por: Chakrabarti, S, et al.
Publicado: (2003)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
por: Hale, G, et al.
Publicado: (2002)

CAMPATH-IH in multiple sclerosis.
por: Moreau, T, et al.
Publicado: (1996)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
por: Potter, M, et al.
Publicado: (2000)

Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients.
por: Calne, R, et al.
Publicado: (1999)

Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
por: Trzonkowski, P, et al.
Publicado: (2006)

Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression.
por: Trzonkowski, P, et al.
Publicado: (2006)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
por: Chakrabarti, S, et al.
Publicado: (2004)

CAMPATH-1H for the treatment of acute rejection in kidney transplant recipients: 10 year follow-up
por: Clatworthy, MR, et al.
Publicado: (2007)

Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients.
por: Calne, R, et al.
Publicado: (1998)

CAMPATH: from concept to clinic.
por: Waldmann, H, et al.
Publicado: (2005)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
por: Russell, N, et al.
Publicado: (1999)

CAMPATH-1 antibodies in stem-cell transplantation.
por: Hale, G, et al.
Publicado: (2001)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
por: Clatworthy, MR, et al.
Publicado: (2009)

Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality.
por: Chakrabarti, S, et al.
Publicado: (2002)

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.
por: Heit, W, et al.
Publicado: (1986)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
por: Williams, R, et al.
Publicado: (2000)

CAMPATH-1H in inflammatory arthritis.
por: Watts, R, et al.
Publicado: (1993)

Specificity of monoclonal antibody Campath-1.
por: Hale, G, et al.
Publicado: (1988)

The CAMPATH-1 antigen (CDw52).
por: Hale, G, et al.
Publicado: (1990)

Allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-Campath conditioning: An effective regime with low procedure-related toxicity.
por: Cull, G, et al.
Publicado: (1999)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
por: Hale, G, et al.
Publicado: (1996)

Graft failure in allogeneic hematopoietic stem cell recipients: diagnosis and treatment
por: U. V. Maslikova, et al.
Publicado: (2023-03-01)

Analysis of the results of allogeneic hematopoietic stem cell transplantation depending on HLA matching of the unrelated donor / recipient pair
por: Ye. V. Kuzmich, et al.
Publicado: (2015-01-01)

Analysis of the results of allogeneic hematopoietic stem cell transplantation depending on HLA matching of the unrelated donor / recipient pair
por: Ye. V. Kuzmich, et al.
Publicado: (2015-01-01)

Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.
por: Jérome Kluza, et al.
Publicado: (2011-01-01)

Sequential allogeneic and autologous CAR-T–cell therapy to treat an immune-compromised leukemic patient
por: Jian-Ping Zhang, et al.
Publicado: (2018-07-01)

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
por: Cull, G, et al.
Publicado: (2000)

Low T-Cell Responses to Mitogen Stimulation Predicts Poor Survival in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation
por: Michelle K. Yong, et al.
Publicado: (2017-11-01)